Synergistic Anticancer Activity of N-Hydroxy-7-(2-Naphthylthio) Heptanomide, Sorafenib, and Radiation Therapy in Patient-Derived Anaplastic Thyroid Cancer Models
Open Access
- 7 January 2021
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (2), 536
- https://doi.org/10.3390/ijms22020536
Abstract
Anaplastic thyroid cancer (ATC) is an undifferentiated and advanced form of thyroid cancer, accompanied with a high ratio of epigenetic adjustment, which occurs more than genetic mutations. In this study, we aimed to evaluate the synergistic anticancer effect (in vitro and in vivo) of the new combination of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA) and sorafenib with radiation therapy in pre-clinical models of ATC. The ATC cell lines, YUMC-A1 and YUMC-A2, were isolated from the current patients who were treated with HNHA and sorafenib, either as monotherapy or combination therapy. Synergistic anticancer effect of the combination therapy on the intracellular signaling pathways and cell cycle was assessed via flow cytometry and immunoblot analysis. To examine tumor shrinkage activity in vivo, an ATC cell line-derived mouse xenograft model was used. Results showed that the combination therapy of HNHA and sorafenib with radiation promoted tumor suppression via caspase cleavage and cell cycle arrest in patient-derived ATC. In addition, the combination therapy of HNHA and sorafenib with radiation was more effective against ATC than therapy with HNHA or sorafenib with radiation. Thus, the combination of HNHA and sorafenib with radiation may be used as a novel curative approach for the treatment of ATC.Funding Information
- National Research Foundation of Korea (NRF-2017R1D1A1B03029716)
- Korea Health Industry Development Institute (HI18C1188)
This publication has 61 references indexed in Scilit:
- Sensitive detection of somatic point mutations in impure and heterogeneous cancer samplesNature Biotechnology, 2013
- Sorafenib and HDAC inhibitors synergize to kill CNS tumor cellsCancer Biology & Therapy, 2012
- Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapyCancer Biology & Therapy, 2011
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugsOncogene, 2009
- High-Resolution, Small Animal Radiation Research Platform With X-Ray Tomographic Guidance CapabilitiesInternational Journal of Radiation Oncology*Biology*Physics, 2008
- Discovery and development of sorafenib: a multikinase inhibitor for treating cancerNature Reviews Drug Discovery, 2006
- Prevalence, Clinical and Ultrasonographic Characteristics of Thyroid IncidentalomasThyroid®, 2004
- Papillary and follicular thyroid carcinomaBest Practice & Research Clinical Endocrinology & Metabolism, 2000
- Papillary and Follicular Thyroid CarcinomaThe New England Journal of Medicine, 1998